Groh Matthias, Lufino Michele M P, Wade-Martins Richard, Gromak Natalia
Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
PLoS Genet. 2014 May 1;10(5):e1004318. doi: 10.1371/journal.pgen.1004318. eCollection 2014 May.
Friedreich ataxia (FRDA) and Fragile X syndrome (FXS) are among 40 diseases associated with expansion of repeated sequences (TREDs). Although their molecular pathology is not well understood, formation of repressive chromatin and unusual DNA structures over repeat regions were proposed to play a role. Our study now shows that RNA/DNA hybrids (R-loops) form in patient cells on expanded repeats of endogenous FXN and FMR1 genes, associated with FRDA and FXS. These transcription-dependent R-loops are stable, co-localise with repressive H3K9me2 chromatin mark and impede RNA Polymerase II transcription in patient cells. We investigated the interplay between repressive chromatin marks and R-loops on the FXN gene. We show that decrease in repressive H3K9me2 chromatin mark has no effect on R-loop levels. Importantly, increasing R-loop levels by treatment with DNA topoisomerase inhibitor camptothecin leads to up-regulation of repressive chromatin marks, resulting in FXN transcriptional silencing. This provides a direct molecular link between R-loops and the pathology of TREDs, suggesting that R-loops act as an initial trigger to promote FXN and FMR1 silencing. Thus R-loops represent a common feature of nucleotide expansion disorders and provide a new target for therapeutic interventions.
弗里德赖希共济失调(FRDA)和脆性X综合征(FXS)是与重复序列扩增相关的40种疾病中的两种(TREDs)。尽管它们的分子病理学尚未完全了解,但有人提出在重复区域形成抑制性染色质和异常DNA结构可能起作用。我们的研究现在表明,RNA/DNA杂交体(R环)在患者细胞中在内源性FXN和FMR1基因的扩增重复序列上形成,这与FRDA和FXS相关。这些转录依赖性R环是稳定的,与抑制性H3K9me2染色质标记共定位,并阻碍患者细胞中的RNA聚合酶II转录。我们研究了FXN基因上抑制性染色质标记与R环之间的相互作用。我们表明,抑制性H3K9me2染色质标记的减少对R环水平没有影响。重要的是,用DNA拓扑异构酶抑制剂喜树碱处理增加R环水平会导致抑制性染色质标记上调,从而导致FXN转录沉默。这在R环与TREDs的病理学之间提供了直接的分子联系,表明R环作为促进FXN和FMR1沉默的初始触发因素。因此,R环代表了核苷酸扩增疾病的一个共同特征,并为治疗干预提供了新的靶点。